Suppr超能文献

肺动脉高压治疗中的新兴生物材料和生物纳米界面:个性化治疗的变革性策略。

Emerging biomaterials and bio-nano interfaces in pulmonary hypertension therapy: transformative strategies for personalized treatment.

作者信息

Chen Xiaofa, Xu Lina, Shi Haiyan

机构信息

Department of Respiratory medicine, Nantong Third People's Hospital, Nantong, China.

出版信息

Front Bioeng Biotechnol. 2025 May 9;13:1567783. doi: 10.3389/fbioe.2025.1567783. eCollection 2025.

Abstract

Pulmonary hypertension (PH) is still an aggressive and progressive illness with vascular remodeling and right heart failure despite the therapeutic advances made in the recent past. Biomaterials offer an attractive route to break the current therapeutic paradigms by inducing vascular repair, facilitating drug targeting, and allowing dynamic regeneration of tissue. This review taking an integrated approach investigates the revolutionary role played by novel biomaterials and bio-nano interfaces in PH treatment. We classify and evaluate several classes of biomaterial platforms including natural polymers, scaffolds based on synthetic polymers, extracellular vesicles (EVs), and stimulus-responsive systems with an emphasis on both underlying mechanisms and clinical relevance. We further address the progress made in artificial intelligence (AI)-based biomaterials and in integrating multi-omics tools to provide patient-tailored therapy. We finally touch on the ongoing limitations and enumerate future directions required to take forward biomaterial-based therapies towards clinical reality.

摘要

尽管近年来在治疗方面取得了进展,但肺动脉高压(PH)仍然是一种具有血管重塑和右心衰竭的侵袭性、进行性疾病。生物材料通过诱导血管修复、促进药物靶向和实现组织动态再生,为打破当前治疗模式提供了一条有吸引力的途径。本综述采用综合方法,研究新型生物材料和生物纳米界面在PH治疗中所起的革命性作用。我们对几类生物材料平台进行分类和评估,包括天然聚合物、基于合成聚合物的支架、细胞外囊泡(EVs)和刺激响应系统,重点关注其潜在机制和临床相关性。我们还讨论了基于人工智能(AI)的生物材料以及整合多组学工具以提供个性化患者治疗方面取得的进展。我们最后提及目前存在的局限性,并列举将基于生物材料的疗法推向临床实际所需的未来方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fffb/12099014/ae7b2ac11dfa/fbioe-13-1567783-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验